Background:
Pumitamig is an experimental immunotherapy that helps the immune system better recognize and attack kidney cancer cells. It works by bringing immune cells closer to the cancer cells. Researchers are still studying its safety and effectiveness.
Ipilimumab is an immunotherapy that boosts the immune system’s ability to fight cancer. It removes a natural “brake,” allowing immune cells to attack cancer more strongly. It is already used in some kidney cancer treatments.
Cabozantinib is a targeted therapy taken as a pill. It blocks signals that help cancer cells grow and form new blood vessels, which can slow or stop cancer growth.
Nivolumab is an immunotherapy that helps the immune system find cancer cells. It blocks a signal cancer uses to hide, allowing immune cells to better attack kidney cancer.
The Trial:
This study is looking at the safety and effectiveness of different treatment options for people with advanced kidney cancer (renal cell carcinoma).
Participants will be randomly assigned to a treatment group. The treatment groups may include one or more of the following medicines: Pumitamig, Ipilimumab, Cabozantinib, Nivolumab.
The trial is not “blind”, so both you and your doctor will know which therapy you are receiving.
Basic Eligibility:
- advanced kidney cancer (renal cell carcinoma) that cannot be removed with surgery or treated with radiation, or has spread to other parts of the body
- Have either clear cell or non-clear cell kidney cancer.
- Cannot have untreated cancer spread to the brain or spinal cord
Additional eligibility criteria will apply. Please speak to your doctor.
| Hospital / Cancer Centre | Principal Investigator | Location | Trial Status |
|---|---|---|---|
| Hospital / Cancer CentreTom Baker Cancer Centre | Principal InvestigatorNot Given | LocationCalgary, AB | Trial StatusNot yet recruiting |
| Hospital / Cancer CentreNotre Dame Hospital | Principal InvestigatorNot Given | LocationMontreal, QC | Trial StatusNot yet recruiting |
| Hospital / Cancer CentreJewish General Hospital | Principal InvestigatorNot Given | LocationMontreal QC | Trial StatusNot yet recruiting |

























































